The estimated Net Worth of Ronald Asbury Andrews is at least $3.91 Million dollars as of 1 December 2022. Mr. Andrews owns over 250,000 units of Oncocyte stock worth over $1,807,957 and over the last 13 years he sold OCX stock worth over $0. In addition, he makes $2,102,210 as President, Chief Executive Officer, and Director at Oncocyte.
Ronald has made over 11 trades of the Oncocyte stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 250,000 units of OCX stock worth $775,000 on 1 December 2022.
The largest trade he's ever made was exercising 250,000 units of Oncocyte stock on 1 December 2022 worth over $775,000. On average, Ronald trades about 15,831 units every 99 days since 2012. As of 1 December 2022 he still owns at least 583,212 units of Oncocyte stock.
You can see the complete history of Mr. Andrews stock trades at the bottom of the page.
Ronald A. Andrews Jr. serves as President, Chief Executive Officer, Director of the Company. Mr. Andrews is the founder and former principal of the Bethesda Group, a consulting firm that advises companies in the molecular diagnostics and genomics fields. Prior to founding the Bethesda Group in 2015, Mr. Andrews served as President, Genetic Sciences Division of Thermo Fisher Scientific from September 2013 to December 2014, and as President, Medical Sciences Venture for Life Technologies from February 2012 to September 2013 when Life Technologies was acquired by Thermo Fisher. From 2004 to December 2010, Mr. Andrews was the Chief Executive Officer and Vice Chairman of the Board of Clarient, Inc., a cancer diagnostics company, and from December 2010 to February 2012 he served as CEO of GE Molecular Diagnostics after Clarient was acquired by GE Healthcare. Mr. Andrews also held management positions with companies in diagnostics and related medical fields, including Roche Molecular Diagnostics, Immucor, Inc. and Abbott Labs. Mr. Andrews also serves as a director of Oxford ImmunoTec. Mr. Andrews is also a member of the Board of Governors of CancerLinQ LLC, a wholly-owned non-profit subsidiary of the American Society of Clinical Oncology.
As the President, Chief Executive Officer, and Director of Oncocyte, the total compensation of Ronald Andrews at Oncocyte is $2,102,210. There are no executives at Oncocyte getting paid more.
Ronald Andrews is 60, he's been the President, Chief Executive Officer, and Director of Oncocyte since 2019. There are 5 older and 2 younger executives at Oncocyte. The oldest executive at Oncocyte Corporation is Dr. Michael D. West Ph.D., 68, who is the Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc..
Ronald's mailing address filed with the SEC is C/O PRECIPIO, INC., 4 SCIENCE PARK, NEW HAVEN, CT, 06511.
Over the last 9 years, insiders at Oncocyte have traded over $16,389,842 worth of Oncocyte stock and bought 56,056,405 units worth $102,313,246 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Cell Therapeutics, Inc. Lin..., and Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of $3,382,106. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth $10,001.
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
Oncocyte executives and other stock owners filed with the SEC include: